Nav-gal
Nav-gal has been studied in 2 papers since 2020: none in people yet, 1 in animals, 1 review. The research so far is in animals. The newest paper, Mar 10, 2022: “Strategies to Reduce the On-Target Platelet Toxicity of Bcl-xL Inhibitors: PROTACs, SNIPERs and Prodrug-Based Approaches”.
2 papers study it6 findingsUpdated
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Cancer Research UK and 6 more
- 6 of 6 findings with company ties
- Animals1
What did studies of Nav-gal find?
6Studies of Nav-gal measured 6 outcomes; the most studied are thrombocytopenia (1 study), platelet apoptosis (1) and tumor growth (1).
Thrombocytopenia
downin mice1
1 study
Thrombocytopenia
downin mice1
Nav-gal decreases thrombocytopenia in mice.
“galacto-conjugation reduces Navitoclax-induced platelet apoptosis in human and murine blood samples treated ex vivo, and thrombocytopenia at therapeutically effective concentrations in murine lung cancer models.”
Animalscompared with navitoclax; at therapeutically effective concentrations; murine lung cancer modelsgalacto-conjugated prodrug
Aging cell
platelet apoptosis
downin human cells1
1 study
platelet apoptosis
downin human cells1
Nav-gal decreases platelet apoptosis in human cells (compared with navitoclax; human blood samples ex vivo).
“galacto-conjugation reduces Navitoclax-induced platelet apoptosis in human and murine blood samples treated ex vivo”
Cellscompared with navitoclax; human blood samples ex vivogalacto-conjugated prodrugplatelet
Aging cell
Tumor growth
downin mice1
1 study
Tumor growth
downin mice1
Nav-gal decreases tumor growth in mice with cisplatin; in vivo.
“Concomitant treatment with cisplatin and Nav-Gal in vivo results in the eradication of senescent lung cancer cells and significantly reduces tumour growth.”
Animalswith cisplatin; in vivogalacto-conjugated prodruglung cancer
Aging cell
Senescent lung cancer cells
downin mice1
1 study
Senescent lung cancer cells
downin mice1
Nav-gal decreases senescent lung cancer cells in mice with cisplatin; in vivo.
“Concomitant treatment with cisplatin and Nav-Gal in vivo results in the eradication of senescent lung cancer cells and significantly reduces tumour growth.”
Animalswith cisplatin; in vivogalacto-conjugated prodruglung cancer
Aging cell
Cisplatin cytotoxicity
upin human cells1
1 study
Cisplatin cytotoxicity
upin human cells1
Nav-gal increases cisplatin cytotoxicity in human cells with cisplatin.
“Nav-Gal enhances the cytotoxicity of standard senescence-inducing chemotherapy (cisplatin) in human A549 lung cancer cells.”
Cellswith cisplatingalacto-conjugated prodrugA549 lung cancer cells
Aging cell
Apoptosis
upin cells1
1 study
Apoptosis
upin cells1
Nav-gal induces apoptosis in cells (senescent cells).
“Nav-Gal selectively induces senescent cell apoptosis”
Cellssenescent cellsgalacto-conjugated prodrug
Aging cell